Core Viewpoint - The transition of Jiang Ying from a fund manager at Guotai Fund to the Secretary of the Board at Luoxin Pharmaceutical reflects a growing trend of fund managers diversifying their career paths beyond traditional asset management roles [2][5][11]. Group 1: Jiang Ying's Background and Transition - Jiang Ying, born in October 1987, holds dual degrees in Science and Economics from Peking University, as well as a Master's in Management from Peking University and a Master's in Finance from the University of Hong Kong [5][11]. - She has over four years of experience as a fund manager at Guotai Fund, managing several funds including Guotai Science and Technology Innovation Board Two-Year Open and Guotai Small and Medium Growth [5][6]. - Jiang's management of funds resulted in varying returns, with Guotai Science and Technology Innovation Board Two-Year Open and Guotai Small and Medium Growth showing returns of approximately -12.48% and -34.28% respectively [6][8]. Group 2: Luoxin Pharmaceutical's Performance - Luoxin Pharmaceutical reported a revenue of 1.077 billion yuan in the first half of 2025, a decrease of 14.45% compared to the same period in 2024, while net profit attributable to shareholders increased by 119.95% to 17.695 million yuan [8][10]. - The company's stock price closed at 5.03 yuan per share on October 15, 2024, reflecting a significant decline of over 81% from its peak of 27.94 yuan per share since its listing [8][10]. Group 3: Industry Trends and Implications - The trend of fund managers transitioning to roles in listed companies is becoming more common, with at least four other fund managers making similar moves to become board secretaries [15]. - The number of fund managers has increased from 3,280 in 2022 to 4,072 by October 15, 2025, indicating a growing pool of talent in the industry [11][12]. - The shift in career paths among fund managers is influenced by various factors, including changes in industry dynamics, compensation structures, and the desire for diversified career opportunities [18].

Group 1 - The article discusses the trend of financial professionals, particularly fund managers, transitioning to different roles, such as company secretaries, amid fluctuating fund performance [2] - Jiang Ying has been appointed as the new company secretary of Luoxin Pharmaceutical, succeeding Han Fengsheng, who resigned [2] - Jiang Ying holds dual degrees in Science and Economics from Peking University, as well as a Master's in Management from Peking University and a Master's in Finance from the University of Hong Kong [2] Group 2 - Jiang Ying's previous performance as a fund manager at Guotai Fund was subpar, with all three funds she managed showing losses during her tenure [4] - The funds managed by Jiang Ying include Guotai Science and Technology Innovation Board Two-Year Fixed Opening, which had a return of -12.48%, Guotai Small and Medium Growth with -34.28%, and Guotai Golden Bull Innovative Growth with -7.01% [4] - Despite the losses, the rankings of Guotai Science and Technology Innovation Board Two-Year Fixed Opening and Guotai Golden Bull Innovative Growth were within the top 50% of their respective categories [3] Group 3 - Jiang Ying's predecessor, Han Fengsheng, saw a steady increase in annual salary from 424,100 yuan in 2022 to 845,700 yuan in 2024 [3] - The article raises questions about Jiang Ying's potential income after transitioning from the fund industry to a corporate role [3]

Group 1 - The article discusses the trend of fund managers transitioning to roles as company secretaries in listed companies, indicating a shift beyond asset management [1][4] - Jiang Ying has been appointed as the new company secretary of Luoxin Pharmaceutical, marking a notable case of a fund manager moving into this role [2][3] - Jiang Ying has a strong academic background with dual degrees in Science and Economics from Peking University, and a Master's in Management and Finance from Hong Kong University, but lacks prior experience as a company secretary [3] Group 2 - Luoxin Pharmaceutical reported a revenue of 1.077 billion yuan for the first half of 2025, a year-on-year decrease of 14.45%, while achieving a net profit of 17.695 million yuan, indicating a turnaround from losses in the previous year [4] - The company has faced significant performance fluctuations in recent years, attributed to factors such as the COVID-19 pandemic, impairment provisions, and adjustments in financial liabilities [4] - The trend of hiring former financial professionals as company secretaries has been noted, with examples including Wang Shangbo from Hongtu Innovation Fund and Liu Haoyu from Dongwu Fund, who have transitioned to roles in listed companies [4]

Core Viewpoint - The trend of fund managers transitioning to roles as company secretaries in listed firms is increasing, indicating a shift beyond traditional asset management roles [2][6]. Group 1: Fund Manager Transition - More fund managers are being appointed as company secretaries in listed companies, a trend that has been observed since 2024 [2][6]. - The case of Jiang Ying, a former fund manager at Guotai Fund, being appointed as the secretary of Luoxin Pharmaceutical highlights this trend [3][6]. - Jiang Ying has a strong academic background with degrees from Peking University and the University of Hong Kong, but lacks prior experience as a company secretary [3][6]. Group 2: Company Performance - Luoxin Pharmaceutical, founded in 1988, has a diverse product range covering various medical fields, but has faced significant performance fluctuations in recent years [6]. - The company reported a revenue of 1.077 billion yuan for the first half of 2025, a decrease of 14.45% year-on-year, while achieving a net profit of 17.695 million yuan, marking a return to profitability [6][7]. - The financial performance of Luoxin Pharmaceutical has been impacted by factors such as the COVID-19 pandemic and adjustments in financial liabilities [6][7]. Group 3: Broader Industry Trends - The trend of financial professionals moving into corporate roles is not limited to fund managers; there are also instances of analysts and investment bankers transitioning to company secretary positions [8][9]. - The hiring of former fund managers for roles in research and development within companies, such as Liu Haoyu at Donghua Energy, indicates a diversification of career paths for financial professionals [9].